{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:50:30Z","timestamp":1790178630163,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1124\/dmd.30.3.235","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:17:35Z","timestamp":1042672655000},"page":"235-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["(+)-N-3-Benzyl-Nirvanol and (\u2212)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19"],"prefix":"10.1016","volume":"30","author":[{"given":"Hisashi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Byron","family":"Kneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Haining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Trager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan E.","family":"Rettie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.30.3.235_bib1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0090-9556(25)08481-8","article-title":"Role of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.","volume":"24","author":"Bajpai","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2165\/00003088-199732030-00004","article-title":"Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.","volume":"32","author":"Bertz","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.30.3.235_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(25)12826-7","article-title":"Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.","volume":"277","author":"Bourrie","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.30.3.235_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/tx9701687","article-title":"Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.","volume":"11","author":"Chen","year":"1998","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.30.3.235_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/abbi.1997.9964","article-title":"Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.","volume":"341","author":"Draper","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.3.235_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1006\/abbi.1996.0414","article-title":"Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.","volume":"333","author":"Haining","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.3.235_bib7","first-page":"133","article-title":"Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low Km diazepam. N-demethylases.","volume":"25","author":"Jung","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2125.2000.00175.x","article-title":"In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.","volume":"49","author":"Ko","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.30.3.235_bib9","first-page":"36","article-title":"Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.","volume":"29","author":"Kobayashi","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1995.tb05793.x","article-title":"The effects of selective serotonin reuptake inhibitors and their metabolisms on S-mephenytoin 4\u2032-hydroxylase activity in human liver microsomes.","volume":"40","author":"Kobayashi","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.30.3.235_bib11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0090-9556(25)06862-X","article-title":"Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications.","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.30.3.235_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-199602000-00002","article-title":"P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.","volume":"6","author":"Nelson","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.3.235_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes.","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00498259609046742","article-title":"Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes.","volume":"26","author":"Ono","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.30.3.235_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/004982598238886","article-title":"Inhibition and induction of human cytochrome P450 (CYP) enzymes.","volume":"28","author":"Pelkonen","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.30.3.235_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0090-9556(25)08754-9","article-title":"Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.","volume":"17","author":"Rettie","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib18","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/bi00227a012","article-title":"Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.","volume":"30","author":"Romkes","year":"1991","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.30.3.235_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1990.tb03687.x","article-title":"Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.","volume":"29","author":"Schellens","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.30.3.235_bib20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0022-3565(25)38409-0","article-title":"Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.","volume":"266","author":"Stevens","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"10.1124\/dmd.30.3.235_bib21","first-page":"218","article-title":"Hydantoin and barbiturate inhibitors of CYP2C19 and CYP2C9.","volume":"32","author":"Suzuki","year":"2000","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.30.3.235_bib22","unstructured":"Thummel KE, Kunze KL, Shen DD (2000) Metabolically-based drug-drug interactions: principles and mechanisms Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M ed) pp 3\u201319, Lippincot Williams and Wilkins, Philadelphia, PA."},{"key":"10.1124\/dmd.30.3.235_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00008571-199602000-00007","article-title":"Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.","volume":"6","author":"VandenBranden","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.3.235_bib24","first-page":"1102","article-title":"Escitalopram (s-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to r-citalopram.","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism.","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"key":"10.1124\/dmd.30.3.235_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.pharmtox.40.1.133","article-title":"High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.","volume":"40","author":"White","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.30.3.235_bib27","first-page":"610","article-title":"Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.","volume":"24","author":"Wienkers","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.3.235_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism.","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.30.3.235_bib29","first-page":"433","article-title":"Clomipramine N-demethylation metabolism in human liver microsomes.","volume":"19","author":"Wu","year":"1998","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"10.1124\/dmd.30.3.235_bib30","first-page":"897","article-title":"Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro.","volume":"26","author":"Zhang","year":"2001","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624043873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624043873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.30.3.235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:14:40Z","timestamp":1739902480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624043873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0090955624043873"],"URL":"https:\/\/doi.org\/10.1124\/dmd.30.3.235","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"(+)-N-3-Benzyl-Nirvanol and (\u2212)-N-3-Benzyl-Phenobarbital: New Potent and Selective in Vitro Inhibitors of CYP2C19","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.30.3.235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}